Events,
n/N (%)
Median PFS, months
(95% CI)
Pani + FOLFOX4
156/259 (60)
10.1 (9.3
‒
12.0)
FOLFOX4
170/253 (67)
7.9 (7.2
‒
9.3)
PANITUMUMAB + QT vs
Quimioterapia
FOLFOX
Douillard J-Y, et al. N Engl J Med 2013;369:1023–1034.
PFS
OS
Ensayo fase III PRIME (RAS wt*)
10.1
7.9
HR=0.72
(95% CI: 0.58–0.90)
p=0.004
Proportion event-free, %
40
20
0
60
80
100
0
2
4
6
8 10 12 14 16 18 20 22
Months
12
24
36
48
60
72
0
25.8
20.2
OS estimate, %
0
20
40
60
80
100
HR=0.77
(95% CI: 0.64–0.94)
p=0.009
Months
Events,
n/N (%)
Median OS, months
(95% CI)
Pani + FOLFOX4
204/259 (79)
25.8 (21.7
‒
29.7)
FOLFOX4
218/253 (86)
20.2 (17.6
‒
23.6)
